Service 06 · value dossier
Pharmacoeconomics / HEOR
The economic case that sustains your price with the payer. Cost-effectiveness, cost-utility and budget impact models built to ISPOR standards, with the structure the evaluator expects to find.
- Duration
- 12–20 wks
- Standard
- ISPOR
- Perspective
- Public and private payer
- Deliverable
- Value dossier
When to use it
When the decision is no longer the physician's, it is the payer's
Formulary inclusion, institutional negotiation or price defence against an incoming generic: in all three the argument has to be in the evaluator's language, with outcomes, costs and time horizon made explicit.
-
Is my product cost-effective against the current standard of care in Mexico?
-
What is the ICER, and how does it compare against the reference threshold?
-
What is the impact on the institutional budget over five years?
-
Which assumption is the weakest part of my case, and how do I shield it?
Methodology
From model to a value dossier
-
Stage 01
Evidence
Systematic review of efficacy, safety and utilities, with quality appraisal and extraction of the parameters feeding the model.
-
Stage 02
Costing
Local micro-costing of resources with current institutional tariffs: drug, administration, adverse-event management and cost of treatment failure.
-
Stage 03
Model
Decision tree or Markov model according to the natural history of the disease, with justified horizon and discount rate.
-
Stage 04
Sensitivity
Deterministic and probabilistic analysis, acceptability curve and cost-effectiveness plane to bound the uncertainty of the result.
The model is delivered functional and documented, with the structure and level of detail an institutional submission requires. No black box.
Deliverables
What you receive
-
Value dossier
Complete file with clinical, economic and epidemiological evidence in the format the evaluator expects to receive.
-
Functional model
Model delivered in Excel®, with editable parameters and executable sensitivity analysis.
-
Budget impact analysis
Five-year projection of the effect on institutional spend, with uptake scenarios.
-
Executive summary
Two-page version with the core argument, for negotiation and for committee.
Frequently asked
What clients usually ask
- What cost-effectiveness threshold applies in Mexico?
- There is no single official threshold. We report the ICER against GDP per capita references and against comparable prior decisions, and explain the limitation of both criteria.
- Can it be done without our own clinical trial?
- Yes, using published evidence for the therapeutic set and indirect comparison where applicable. The limitation is declared and subjected to sensitivity analysis.
- Does it include support during the submission?
- We can take part in preparing the response to evaluator observations. We do not replace your access team, we back it technically.
- Do I need the epidemiological model first?
- It helps considerably. Budget impact depends on the eligible universe; if none exists, we build it as part of the scope.
Request a proposal
Tell us the indication, the physician audience and the date you need the result. We respond with design, sample, timing and price.